Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28449888 | 0.95 | HDAC1 (0.70) | HDAC1HDAC2HDAC3HDAC6HDAC8 | |
| SCHEMBL6849672 | 0.84 | LMNA (0.60) | HDAC1HDAC2HDAC3HDAC6HDAC8 | |
| SCHEMBL8249818 | 0.84 | HDAC1 (0.69) | HDAC1HDAC2HDAC3HDAC6HDAC8 | |
| SCHEMBL21149882 | 0.83 | HDAC1 (0.71) | HDAC1HDAC2HDAC3HDAC6HDAC8 | |
| SCHEMBL22190340 | 0.81 | HDAC1 (0.69) | HDAC1HDAC2HDAC3HDAC6HDAC8 | |
| SCHEMBL22190394 | 0.81 | HDAC1 (0.69) | HDAC1HDAC2HDAC3HDAC6HDAC8 | |
| SCHEMBL5020669 | 0.81 | HDAC1 (0.93) | HDAC1HDAC2HDAC3HDAC6HDAC8 | |
| SCHEMBL22190399 | 0.81 | HDAC1 (0.90) | HDAC1HDAC2HDAC3HDAC6HDAC8 | |
| SCHEMBL5020670 | 0.81 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC6HDAC8 | |
| Phenylbutyrylhydroxamic Acid SCHEMBL1350853 | 0.81 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168717-A1 | NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME | INSTITUTE FOR BASIC SCIENCE (KR) | 2022-06-02 | — | — | US | disclosed |
| US-11344872-B2 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | INSTITUTE FOR BASIC SCIENCE (KR) | 2022-05-31 | — | — | US | disclosed |
| US-20200330969-A1 | NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-10-22 | — | — | US | disclosed |
| WO-2019135600-A1 | NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME | 기초과학연구원 | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168717-A1 | NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME | COASY, NOTUM, MRPL21 | HDAC1 1597/4885HDAC2 2165/4885HDAC3 4052/4885 |
| US-11344872-B2 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | COASY, NOTUM, MRPL21 | HDAC1 1465/4885HDAC2 1983/4885HDAC3 3971/4885 |
| US-20200330969-A1 | NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME | COASY, NOTUM, MRPL21 | HDAC1 1597/4885HDAC2 2165/4885HDAC3 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.